ÇEVRESEL BİR ENDOKRİN BOZUCU KİMYASAL: BİSFENOL A VE POLİKİSTİK OVER SENDROMU OLUŞUMUNDA OLASI ETKİLERİ

Abstract views: 59 / PDF downloads: 54

Authors

  • Naile Merve Güven ANKARA ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ
  • Benay Can Eke

Keywords:

PKOS, , BPA,, insülin direnci, , hiperandrojenemi

Abstract

Üreme çağındaki kadınlar arasında yaygın olarak gözlenen endokrin bozukluklardan birisi olan polikistik over sendromunun temel özellikleri arasında klinik ve/veya biyokimyasal hiperandrojenizm, ovulatuar disfonksiyon ve polikistik over morfolojisi bulunmaktadır. PKOS başlıca infertilite olmak üzere insülin direnci, obezite,  tip 2 diabetes mellitus, kardiyovasküler hastalıklar, endometrium, meme ve over kanseri gibi ikincil durumlar ile de ilişkilendirilmektedir. Etiyolojisi açık olmamakla birlikte genetik ve çevresel faktörler sendromun oluşumunda rol oynamaktadır. Genetik temele dayanan ailesel geçişlerin yanı sıra birden fazla moleküler sinyal yolağına ait genlerin PKOS gelişiminden sorumlu olabileceği düşünülmektedir. Çevresel faktörler arasında biyolojik sistemlerde olumsuz etkiye yol açma potansiyeli yüksek olan endokrin bozucu kimyasallar da yer almaktadır. Polikarbonat plastiklerin ve epoksi reçinelerin sentezinde yaygın olarak kullanılan ve güçlü bir endokrin bozucu olduğu bilinen bisfenol A’nın yüksek miktarlarına karşı overlerin hassas olduğunu öne süren kanıtlar bulunmaktadır. Sentetik bir östrojen olan dietilstilbestrole olan benzer kimyasal yapısı nedeniyle BPA nükleer östrojen reseptörünün her iki alt tipine, ERα ve ERβ, bağlanma yeteneğine sahiptir. Bu nedenle, BPA östrojeni taklit eden ve hormon benzeri özellikler gösteren bir ksenoöstrojen olarak kabul edilmektedir. BPA ovaryan steroidogenezini, folikülogenezi ve over morfolojisini değiştirerek kadın üreme sistemini etkileyebilmektedir. Bu derlemede ise BPA maruziyetinin PKOS gelişimindeki olası etkilerini tartışmak amaçlanmıştır.

References

Ashraf, S., Nabi, M., Rasool, S. u. A., Rashid, F., Amin, S. (2019): Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egyptian Journal of Medical Human Genetics, 20:(1). doi: 10.1186/s43042-019-0031-4

Sanchez-Garrido, M. A., Tena-Sempere, M. (2020): Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism, 35:(100937). doi: 10.1016/j.molmet.2020.01.001

Sam, S. (2007): Obesity and polycystic ovary syndrome. Obesity Management, 3:(2) 69-73. doi: 10.1089/obe.2007.0019

Ianosi, S., Ianosi, G., Neagoe, D., Ionescu, O., Zlatian, O., Docea, A. O., Badiu, C., Sifaki, M., Tsoukalas, D., Tsatsakis, A. M., Spandidos, D. A., Calina, D. (2016): Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women. Molecular Medicine Reports, 14:(6) 5501-5506. doi: 10.3892/mmr.2016.5924

Evliyaoğlu, O. (2011): Polikistik over sendromu ve hirsutizm. Türk Pediatri Arşivi, 46:(1) 97-102. doi: 10.4274/tpa.46.45

Siklar, Z., Oçal, G., Adiyaman, P., Ergur, A., Berberoğlu, M. (2007): Functional ovarian hyperandrogenism and polycystic ovary syndrome in prepubertal girls with obesity and/or premature pubarche. Journal of Pediatric Endocrinology and Metabolism, 20:(4) 475-481. doi: 10.1515/jpem.2007.20.4.475

Alataş, E., Kılıç, D., Güler, T. (2019): 2018 Uluslarası kanıta dayalı polikistik over sendromu değerlendirme ve yönetim rehberi doğrultusunda tanıdaki ‘yeniler’ ve ‘yineler’. Pamukkale Medical Journal, 12: 595-602. doi: 10.31362/patd.563485

Housman, E., Reynolds, R. V. (2014): Polycystic ovary syndrome: a review for dermatologists: Part I. diagnosis and manifestations. Journal of the American Academy of Dermatology, 71:(5) 847.e841-847.e810; quiz 857-848. doi: 10.1016/j.jaad.2014.05.007

Özberk, D., Ruhuşen, K., Görkemli, H. (2019): Hirsutizmi olan kadınlarda tanı, insülin direnci ve beden kitle indeksi arasındaki ilişki. Çukurova Medical Journal, 44:(1) 72-79.

Lumezi, B. G., Berisha, V. L., Pupovci, H. L., Goçi, A., Hajrushi, A. B. (2018): Grading of hirsutism based on the Ferriman-Gallwey scoring system in Kosovar women. Postȩpy Dermatologii i Alergologii, 35:(6) 631-635. doi: 10.5114/ada.2018.77615

Acmaz, G., Cınar, L., Acmaz, B., Aksoy, H., Kafadar, Y. T., Madendag, Y., Ozdemir, F., Sahin, E., Muderris, I. (2019): The effects of oral isotretinoin in women with acne and polycystic ovary syndrome. BioMed Research International, 2019:(2513067). doi: 10.1155/2019/2513067

Franik, G., Bizoń, A., Włoch, S., Kowalczyk, K., Biernacka-Bartnik, A., Madej, P. Jul (2018): Hormonal and metabolic aspects of acne vulgaris in women with polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 22:(14) 4411-4418. doi: 10.26355/eurrev_201807_15491

Gainder, S., Sharma, B. (2019): Update on management of polycystic ovarian syndrome for dermatologists. Indian dermatology online journal, 10:(2) 97-105. doi: 10.4103/idoj.IDOJ_249_17

Karrer-Voegeli, S., Rey, F., Reymond, M. J., Meuwly, J.-Y., Gaillard, R. C., Gomez, F. (2009): Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine, 88:(1) 32-45.

Mostafa, M. H., Ragab, N. F., Mohammed, G. F. (2020): Prevalence of cutaneous disorders in patients with polycystic ovary syndrome. Open Journal of Obstetrics and Gynecology, 10:(09) 1246-1264. doi: 10.4236/ojog.2020.1090116

Amiri, M., Ramezani Tehrani, F., Nahidi, F., Bidhendi Yarandi, R., Behboudi-Gandevani, S., Azizi, F. Sep (2017): Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. Clinical Endocrinology (Oxford), 87:(3) 217-230. doi: 10.1111/cen.13389

Leerasiri, P., Wongwananuruk, T., Indhavivadhana, S., Techatraisak, K., Rattanachaiyanont, M., Angsuwathana, S. Jun (2016): Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. The Journal of Obstetrics and Gynaecology Research, 42:(6) 678-683. doi: 10.1111/jog.12945

Chang, R. J., Dumesic, D. A. (2019): Yen & Jaffe's Reproductive Endocrinology Physiology, Pathophysiology, and Clinical Management (Eighth Edition), Elsevier, Philadelphia

Diamanti-Kandarakis, E. (2008): Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Reviews in Molecular Medicine, 10: e3. doi: 10.1017/s1462399408000598

Güzel, A. İ., Aksoy, N., Tokmak, A., Yılmaz, N. (2014): Ovulation induction in polycystic ovary syndrome. Journal of Clinical and Experimental Investigations, 5:(4). doi: 10.5799/ahinjs.01.2014.04.0474

Chang, J., Azziz, R., Legro, R., Dewailly, D. (2004): The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Fertility and Sterility, 81:(1) 19-25.

Adams, J. M., Taylor, A. E., Crowley, W. F., Jr., Hall, J. E. (2004): Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism, 89:(9) 4343-4350. doi: 10.1210/jc.2003-031600

Öztürk, S., Dündar, B., Koçyiğit, N., Çatlı, G. (2018): Polikistik over sendromlu adölesanlarda serum ürokortin 2, ürokortin 3 ve antimüllerian hormon düzeyleri. İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 3:(2) 21-26. doi: https://dergipark.org.tr/tr/pub/ikcusbfd/449981

Öktem, Ö., Urman, B. (2012): Reprodüktif yaşam siklusu: folikülogenez ve menstrüasyon. Türk Jinekoloji ve Obstetrik Derneği Dergisi, 9:(1) 1-24. doi: 10.5505/tjod.2012.37039

Barbieri, R. Steroid hormone metabolism in polycystic ovary syndrome. https://www.uptodate.com/contents/steroid-hormone-metabolism-in-polycystic-ovary-syndrome (accessed 01.09.2021)6

Abbara, A., Eng, P. C., Phylactou, M., Clarke, S. A., Hunjan, T., Roberts, R., Vimalesvaran, S., Christopoulos, G., Islam, R., Purugganan, K., Comninos, A. N., Trew, G. H., Salim, R., Hramyka, A., Owens, L., Kelsey, T., Dhillo, W. S. (2019): Anti-müllerian hormone (AMH) in the diagnosis of menstrual disturbance due to polycystic ovarian syndrome. Frontiers in endocrinology, 10: 656-656. doi: 10.3389/fendo.2019.00656

Hoyt, K. L., Schmidt, M. C. (2004): Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment. Journal of the American Society for Clinical Laboratory Science, 17:(3) 155-163.

Rosenfield, R. L., Ehrmann, D. A. (2016): The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews, 37:(5) 467-520. doi: 10.1210/er.2015-1104

Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., Azziz, R. (2016): Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 106:(1) 6-15. doi: 10.1016/j.fertnstert.2016.05.003

Azziz, R. (2005): Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertility and Sterility, 83:(5) 1343-1346. doi: 10.1016/j.fertnstert.2005.01.085

Şahin, L., Kumbak Aygün, B. (2013): Adolesanda polikistik over sendromu. Fırat Tıp Dergisi, 18:(2) 66-74.

Bani Mohammad, M., Majdi Seghinsara, A. (2017): Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pacific journal of cancer prevention : APJCP, 18:(1) 17-21. doi: 10.22034/APJCP.2017.18.1.17

Tanrıverdi, F. (2009): Sekonder polikistik over durumları. Türkiye Klinikleri Endokrinoloji - Özel Konular, 2:(2) 23-27.

Yildiz, B. O., Bozdag, G., Yapici, Z., Esinler, I., Yarali, H. (2012): Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human Reproduction, 27:(10) 3067-3073. doi: 10.1093/humrep/des232

Sanchez-Garrido, M. A., Tena-Sempere, M. (2020): Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Molecular Metabolism, 35: 100937. doi: 10.1016/j.molmet.2020.01.001

Matalliotakis, I., Kourtis, A., Koukoura, O., Panidis, D. (2006): Polycystic ovary syndrome: etiology and pathogenesis. Archives of Gynecology and Obstetrics, 274:(4) 187-197. doi: 10.1007/s00404-006-0171-x

Yıldırım, H. A., Memişoğulları, R. (2011): Polikistik over sendromu’nda gözlenen biyokimyasal bozukluklar. Konuralp Tıp Dergisi, 3:(1) 42-48.

Coyle, C., Campbell, R. E. (2019): Pathological pulses in PCOS. Molecular and Cellular Endocrinology, 498: 110561. doi: https://doi.org/10.1016/j.mce.2019.110561

Karadeniz, Z. (2018): Polikistik over sendromunda metformin kullanımı. Tıp Fakültesi Klinikleri, 1:(1) 43-57.

Shaw, N., Rosenfield, M. R. L. Etiology and pathophysiology of polycystic ovary syndrome in adolescents. https://www.uptodate.com/contents/etiology-and-pathophysiology-of-polycystic-ovary-syndrome-in-adolescents (accessed 02.09.2021)

Alsadi, B. (2019): Clinical Features of PCOS. In: Polycystic Ovarian Syndrome, Z.W. (ed.), IntechOpen.

Memili, S., Şar, F., Memili, V., Kazancıoğlu, R. (2009): Polikistik over sendromunda insülin direnci ve antropometrik ölçümler. Haseki Tıp Bülteni, 47:(1) 6-12.

Cibula, D. (2004): Is insulin resistance an essential component of PCOS?: the influence of confounding factors. Human Reproduction, 19:(4) 757-759. doi: 10.1093/humrep/deh137

Pateguana, N. B., Janes, A. The contribution of hyperinsulinemia to the hyperandrogenism of polycystic ovary syndrome. Journal of Insulin Resistance, 4:(1). doi: 10.4102/jir.v4i1.50

Essah, P. A., Nestler, J. E. (2006): Insulin Resistance and Hyperinsulinism in the Polycystic Ovary Syndrome, in Androgen Excess Disorders in Women, Humana Press, Totowa, New Jersey

Zhang, B., Wang, J., Shen, S., Liu, J., Sun, J., Gu, T., Ye, X., Zhu, D., Bi, Y. (2018): Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome. BioMed Research International, 2018:(68697059). doi: 10.1155/2018/6869705

Barber, T. M., Hanson, P., Weickert, M. O., Franks, S. (2019): Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clinical Medicine Insights. Reproductive Health, 13:(11795581198740429). doi: 10.1177/1179558119874042

Tsilchorozidou, T., Overton, C., Conway, G. S. (2004): The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology, 60:(1) 1-17. doi: https://doi.org/10.1046/j.1365-2265.2003.01842.x

Lin, Q., Zhang, H., Zhao, J., Wang, Z. (2019): Expression and Contribution of Insulin Signaling Pathway to the Development of Polycystic Ovary Syndrome, In: Polycystic Ovarian Syndrome, Z. W. (ed.), IntechOpen.

Bolu, Ş. E., Taşlıpınar, A. (2006): İnsülin direncinin moleküler mekanizmaları. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi-Metabolik Sendrom Özel Sayısı, 2:(3) 8-17.

Magoffin, D. A. (2006): Ovarian steroidogenic abnormalities in the polycystic ovary syndrome, in Androgen Excess Disorders in Women, Humana Press, Totowa, New Jersey

Bremer, A. A., Miller, W. L. May (2008): The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertility and Sterility, 89:(5) 1039-1048. doi: 10.1016/j.fertnstert.2008.02.091

Koçyiğit, C., Çatlı, G., Dündar, B. N. (2016): Nadir bir olgu: primer amenore ve hipertansiyon; 17 alfa-hidroksilaz/17,20-liyaz eksikliği. Türkiye Klinikleri Journal of Case Reports-Çocuk Endokrinolojisi ve Diyabet Derneği Bahar Okulu 2016 Olgu Sunumları, 24:((2 Suppl 1) 13-17.

González, F. (2012): Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids, 77:(4) 300-305. doi: 10.1016/j.steroids.2011.12.003

Velez, L. M., Seldin, M., Motta, A. B. (2021): Inflammation and reproductive function in women with polycystic ovary syndrome†. Biology of Reproduction, 104:(6) 1205-1217. doi: 10.1093/biolre/ioab050

Aydoğdu, A., Haymana, C., Tapan, S., Taşlıpınar, A., Yazıcı, M., Başaran, Y., Dinç, M., Sönmez, A., Azal, Ö. (2015): Polikistik over sendromu olgularında artmış visseral adipozite indeksi; inflamasyon, insülin direnci ve hiperandrojenite arasındaki ilişki. Gülhane Tıp Dergisi, 57: 107-110.

Hivert, M. F., Baillargeon, J. P. (2006): Environmental Factors in the Polycystic Ovary Syndrome. In: Androgen Excess Disorders in Women, R. A., J. E. N., D. D. Humana Press, New Jersey.

Aksu, B. M., Sarıyer, E. T. (2021): Polikistik over sendromu ve ağırlık yönetimi arasındaki ilişkinin incelenmesi. Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi, 12:(2) 241-249. doi: 10.22312/sdusbed.854552

Merkin, S. S., Phy, J. L., Sites, C. K., Yang, D. (2016): Environmental determinants of polycystic ovary syndrome. Fertility and Sterility, 106:(1) 16-24. doi: 10.1016/j.fertnstert.2016.05.011

Chou, K. (2005): Endocrine System. In: Encyclopedia of Toxicology, P. W. (ed.), Academic Press, London.

Çetinkaya, S. (2009): Endokrin çevre bozucular ve ergenlik üzerine etkileri. Dicle Tıp Dergisi, 36:(1) 59-66.

WHO. IPCS global assessment of EDCs. https://www.who.int/ipcs/publications/en/ch1.pdf (accessed 19.09.2021)

EPA. Special report on environmental endocrine disruption: An effects assessment and analysis. https://archive.epa.gov/raf/web/pdf/endocrine.pdf (accessed 17.09.2021)

Lauretta, R., Sansone, A., Sansone, M., Romanelli, F., Appetecchia, M. (2019): Endocrine disrupting chemicals: effects on endocrine glands. Frontiers in Endocrinology, 10:(178).

Ünsal, Ç., Sarıyar, G. (2008): AntiAging İçin Fitoöstrojenler. Türkiye Klinikleri Tıp Bilimleri Dergisi-1. AntiAging ve Estetik Tıp Kongresi Supplementi, 28:(6) 1 160-165.

Tutanç, L., Cansız, D., Emekli-Alturfan, E., Alturfan, A. A. (2021): Endokrin Bozucu Kimyasallar ve Tekstil Alanında Kullanımları. Experimed, 11:(2) 1-9.

Kerdivel, G., Habauzit, D., Pakdel, F. (2013): Assessment and molecular actions of endocrine-disrupting chemicals that interfere with estrogen receptor pathways. International Journal of Endocrinology, 2013:(501851). doi: 10.1155/2013/501851

Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L. C., Hauser, R., Prins, G. S., Soto, A. M., Zoeller, R. T., Gore, A. C. (2009): Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocrine reviews, 30:(4) 293-342.

Yeşilkaya, E. (2008): Endokrin Bozucular. Güncel Pediatri, 6:(3) 76-82.

Fendoğlu, B. Y., Koçer-Gümüşel, B., Erkekoğlu, P. (2019): Endokrin Bozucu Kimyasal Maddelere ve Etki Mekanizmalarına Genel Bir Bakış. Hacettepe University Journal of the Faculty of Pharmacy, 39:(1) 30-43.

Rolfo, A., Nuzzo, A. M., De Amicis, R., Moretti, L., Bertoli, S., Leone, A. Jun 11 (2020): Fetal-Maternal Exposure to Endocrine Disruptors: Correlation with Diet Intake and Pregnancy Outcomes. Nutrients, 12:(6). doi: 10.3390/nu12061744

Özel, Ş. K. (2016): Genitoüriner anomalilerin gelişiminde hormonlar ve çevresel faktörlerin rolü. Çocuk Cerrahisi Dergisi, 30:(Ek sayı 2) 134-140. doi: 10.5222/JTAPS.2016.134

Atay, S. (2014): Medikal Malzemelerde Kullanılan Di-2-Etilhekzil Fitalatın (DEHP) Ortaya Çıkardığı Hastalık Riskleri. The Journal of Pediatric Research, 1:(3) 113-117. doi: 10.4274/jpr.18291

Yang, O., Kim, H. L., Weon, J.-I., Seo, Y. R. (2015): Endocrine-disrupting Chemicals: Review of Toxicological Mechanisms Using Molecular Pathway Analysis. Journal of cancer prevention, 20:(1) 12-24. doi: 10.15430/JCP.2015.20.1.12

World Health, O., United Nations Environment, P., Inter-Organization Programme for the Sound Management of, C., Bergman, Å., Heindel, J. J., Jobling, S., Kidd, K., Zoeller, T. R., "State of the science of endocrine disrupting chemicals 2012 : summary for decision-makers," World Health Organization, Geneva, 2013 2013. [Online]. Available: https://apps.who.int/iris/handle/10665/78102

Balaguer, P., Delfosse, V., Bourguet, W. (2019): Mechanisms of endocrine disruption through nuclear receptors and related pathways. Current Opinion in Endocrine and Metabolic Research, 7: 1-8.

Altunkaynak, B. Z., Ünal, D., Aksak, S., Ünal, B. (2012): Östrojen hormonu ve menopoz. Deneysel ve Klinik Tıp Dergisi, 29: 252-256.

Warner, G. R., Mourikes, V. E., Neff, A. M., Brehm, E., Flaws, J. A. (2020): Mechanisms of action of agrochemicals acting as endocrine disrupting chemicals. Molecular and Cellular Endocrinology, 502:(110680).

Swedenborg, E., Rüegg, J., Mäkelä, S., Pongratz, I. (2009): Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. Journal of molecular endocrinology, 43:(1) 1-10. doi: 10.1677/jme-08-0132

Balaguer, P., Delfosse, V., Grimaldi, M., Bourguet, W. (2017): Structural and functional evidences for the interactions between nuclear hormone receptors and endocrine disruptors at low doses. Comptes Rendus Biologies, 340: (9-10) 414-420. doi: 10.1016/j.crvi.2017.08.002

De Coster, S.,Van Larebeke, N. (2012): Endocrine-disrupting chemicals: associated disorders and mechanisms of action. Journal of Environmental and Public Health, 2012:(713696).

Combarnous, Y., Nguyen, T. M. D. (2019): Comparative overview of the mechanisms of action of hormones and endocrine disruptor compounds. Toxics, 7:(1) 5. doi: 10.3390/toxics7010005

La Merrill, M. A., Vandenberg, L. N., Smith, M. T., Goodson, W., Browne, P., Patisaul, H. B., Guyton, K. Z., Kortenkamp, A., Cogliano, V. J., Woodruff, T. J., Rieswijk, L., Sone, H., Korach, K. S., Gore, A. C., Zeise, L., Zoeller, R. T. (2020): Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification. Nature Reviews Endocrinology, 16:(1) 45-57. doi: 10.1038/s41574-019-0273-8

Kopras, E., Potluri, V., Bermudez, M. L., Williams, K., Belcher, S., Kasper, S. Apr (2014): Actions of endocrine-disrupting chemicals on stem/progenitor cells during development and disease. Endocrine-Related Cancer, 21:(2) T1-12. doi: 10.1530/erc-13-0360

Allard, P., Colaiácovo, M. P. (2011): Bisphenol A. In: Reproductive and Developmental Toxicology (Second Edition), R. C. G. (ed.), Academic Press, Cambridge, MA, USA

Dodds, E. C., Lawson, W. (1936): Synthetic strogenic agents without the phenanthrene nucleus. Nature, 137:(3476) 996-996.

Mileva, G., Baker, S. L., Konkle, A., Bielajew, C. (2014): Bisphenol-A: epigenetic reprogramming and effects on reproduction and behavior. International Journal of Environmental Research and Public Health, 11:(7) 7537-7561.

Gölge, E., Demirağ, K., Ova, G. (2005): Bir gıda kontaminantı: bisphenol A. Akademik Gıda Dergisi, 3:(3) 16-18.

Hwang, K. A., Choi, K. C. (2015): Chapter One - Endocrine-Disrupting Chemicals with Estrogenicity Posing the Risk of Cancer Progression in Estrogen-Responsive Organs. In Advances in Molecular Toxicology, J. C. F., J. M. H. (ed.), Elsevier, Amsterdam, The Netherlands

Blankenship, A. L., Coady, K. (2005): Bisphenol A. In: Encyclopedia of Toxicology (Second Edition), P. W. (ed.), Academic Press, London.

Jurewicz, J., Majewska, J., Berg, A., Owczarek, K., Zajdel, R., Kaleta, D., Wasik, A., Rachoń, D. 2021/03/01/ (2021): Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome – is there an association? Environmental Pollution, 272:(115962). doi: https://doi.org/10.1016/j.envpol.2020.115962

Demierre, A.-L., Peter, R., Oberli, A., Bourqui-Pittet, M. (2012): Dermal penetration of bisphenol A in human skin contributes marginally to total exposure. Toxicology Letters, 213:(3) 305-308.

Konieczna, A., Rutkowska, A., Rachon, D. (2015): Health risk of exposure to bisphenol A (BPA). Roczniki Państwowego Zakładu Higieny, 66:(1).

Gündoğdu, T.,Akdevelioğlu, Y. (2019): Bisfenol A ve erkek üreme sağlığı. Androloji Bülteni, 21:(32-40).

Almeida, S., Raposo, A., Almeida‐González, M., Carrascosa, C. (2018): Bisphenol A: food exposure and impact on human health. Comprehensive Reviews in Food Science and Food Safety, 17:(6) 1503-1517.

Matuszczak, E., Komarowska, M. D., Debek, W., Hermanowicz, A. (2019): The impact of bisphenol A on fertility, reproductive system, and development: A review of the literature. International Journal of Endocrinology, 2019: (4068717). doi: 10.1155/2019/4068717

Eltoukhy, A., Jia, Y., Nahurira, R., Abo-Kadoum, M. A., Khokhar, I., Wang, J., Yan, Y. Jan 13 (2020): Biodegradation of endocrine disruptor Bisphenol A by Pseudomonas putida strain YC-AE1 isolated from polluted soil, Guangdong, China. BioMed Central Microbiology, 20:(1) 11. doi: 10.1186/s12866-020-1699-9

Gao, H., Yang, B.-J., Li, N., Feng, L.-M., Shi, X.-Y., Zhao, W.-H., Liu, S.-J. (2015): Bisphenol A and hormone-associated cancers: current progress and perspectives. Medicine, 94:(1) e211. doi: 10.1097/md.0000000000000211

Nagel, S. C., Bromfield, J. J. (2013): Bisphenol a: a model endocrine disrupting chemical with a new potential mechanism of action. Endocrinology, 154:(6) 1962-1964. doi: 10.1210/en.2013-1370

Acconcia, F., Pallottini, V., Marino, M. (2015): Molecular mechanisms of action of BPA. Dose-response: a publication of International Hormesis Society, 13:(4) 1559325815610582-1559325815610582. doi: 10.1177/1559325815610582

Ayazgök, B., Tüylü Küçükkılınç, T. (2017): Düşük doz bisfenol A’nın büyük etkileri. FABAD Farmasötik Bilimler Dergisi, 42:(2) 139-150.

Delfosse, V., Grimaldi, M., Pons, J. L., Boulahtouf, A., le Maire, A., Cavailles, V., Labesse, G., Bourguet, W., Balaguer, P. (2012): Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proceedings of the National Academy of Sciences of the United States of America., 109:(37) 14930-14935. doi: 10.1073/pnas.1203574109

Caserta, D., Di Segni, N., Mallozzi, M., Giovanale, V., Mantovani, A., Marci, R., Moscarini, M. (2014): Bisphenol A and the female reproductive tract: an overview of recent laboratory evidence and epidemiological studies. Reproductive Biology and Endocrinology: RB&E, 12:(37-37). doi: 10.1186/1477-7827-12-37

Ptak, A., Hoffmann, M., Rak, A. (2017): The Ovary as a Target Organ for Bisphenol A Toxicity. In: Bisphenol A Exposure and Health Risks, P.E., B. K. G (ed.), IntechOpen.

Zhou, W., Liu, J., Liao, L., Han, S., Liu, J. (2008): Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Molecular and Cellular Endocrinology, 283:(1-2) 12-18. doi: 10.1016/j.mce.2007.10.010

Takeuchi, T., Tsutsumi, O., Ikezuki, Y., Kamei, Y., Osuga, Y., Fujiwara, T., Takai, Y., Momoeda, M., Yano, T., Taketani, Y. (2006): Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocrine Journal, 53:(4) 485-491. doi: 10.1507/endocrj.k06-032

Hanioka, N., Jinno, H., Nishimura, T., Ando, M. (1998): Suppression of male-specific cytochrome P450 isoforms by bisphenol A in rat liver. Archives of Toxicology, 72:(7) 387-394. doi: 10.1007/s002040050518

Sözlü, S., Akdevelioğlu, Y. (2018): Bisfenol A (BFA) ve insan üreme sağlığı. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 11:(1) 86-99.

Fernández, M., Bourguignon, N., Lux-Lantos, V., Libertun, C. (2010): Neonatal exposure to bisphenol a and reproductive and endocrine alterations resembling the polycystic ovarian syndrome in adult rats. Environmental Health Perspectives, 118:(9) 1217-1222. doi: 10.1289/ehp.0901257

Barrett, E. S., Sobolewski, M. (2014): Polycystic ovary syndrome: do endocrine-disrupting chemicals play a role? Seminars in Reproductive Medicine, 32:(3) 166-176. doi: 10.1055/s-0034-1371088

Konieczna, A., Rachoń, D., Owczarek, K., Kubica, P., Kowalewska, A., Kudłak, B., Wasik, A., Namieśnik, J. (2018): Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome. Reproductive Toxicology, 82: 32-37. doi: 10.1016/j.reprotox.2018.09.006

Hossein Rashidi, B., Amanlou, M., Behrouzi Lak, T., Ghazizadeh, M., Haghollahi, F., Bagheri, M., Eslami, B. (2017): The association between bisphenol A and polycystic ovarian syndrome: a case-control study. Acta Medica Iranica, 55:(12) 759-764.

Takeuchi, T., Tsutsumi, O. (2002): Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Biochemical and Biophysical Research Communications, 291:(1) 76-78. doi: 10.1006/bbrc.2002.6407

Takeuchi, T., Tsutsumi, O., Ikezuki, Y., Takai, Y., Taketani, Y. (2004): Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocrine Journal, 51:(2) 165-169. doi: 10.1507/endocrj.51.165

Vagi, S. J., Azziz-Baumgartner, E., Sjödin, A., Calafat, A. M., Dumesic, D., Gonzalez, L., Kato, K., Silva, M. J., Ye, X., Azziz, R. (2014): Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol A in polycystic ovary syndrome: a case-control study. BMC Endocrine Disorders, 14:(86). doi: 10.1186/1472-6823-14-86

Vahedi, M., Saeedi, A., Poorbaghi, S. L., Sepehrimanesh, M., Fattahi, M. (2016): Metabolic and endocrine effects of bisphenol A exposure in market seller women with polycystic ovary syndrome. Environmental Science and Pollution Research, 23: 23546-23550. doi: 10.1007/s11356-016-7573-5

Kawa, I. A., Masood, A., Ganie, M. A., Fatima, Q., Jeelani, H., Manzoor, S., Rizvi, S. M., Muzamil, M., Rashid, F. (2019): Bisphenol A (BPA) acts as an endocrine disruptor in women with polycystic ovary syndrome: hormonal and metabolic evaluation. Obesity Medicine, 14:(100090). doi: https://doi.org/10.1016/j.obmed.2019.100090

Kandaraki, E., Chatzigeorgiou, A., Livadas, S., Palioura, E., Economou, F., Koutsilieris, M., Palimeri, S., Panidis, D., Diamanti-Kandarakis, E. (2011): Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. The Journal of Clinical Endocrinology and Metabolism, 96:(3) E480-484. doi: 10.1210/jc.2010-1658

Akın, L., Kendirci, M., Narin, F., Kurtoglu, S., Saraymen, R., Kondolot, M., Koçak, S., Elmali, F. (2015): The endocrine disruptor bisphenol A may play a role in the aetiopathogenesis of polycystic ovary syndrome in adolescent girls. Acta Paediatrica, 104:(4) e171-177. doi: 10.1111/apa.12885

Akgül, S., Sur, Ü., Düzçeker, Y., Balcı, A., Kızılkan, M. P., Kanbur, N., Bozdağ, G., Erkekoğlu, P., Gümüş, E., Kocer-Gumusel, B., Derman, O. (2019): Bisphenol A and phthalate levels in adolescents with polycystic ovary syndrome. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, 35:(12) 1084-1087. doi: 10.1080/09513590.2019.1630608

Zhou, W., Fang, F., Zhu, W., Chen, Z.-J., Du, Y., Zhang, J. (2016): Bisphenol A and Ovarian Reserve among Infertile Women with Polycystic Ovarian Syndrome. International Journal of Environmental Research and Public Health, 14:(1) 18. doi: 10.3390/ijerph14010018

Wang, Y., Zhu, Q., Dang, X., He, Y., Li, X., Sun, Y. (2017): Local effect of bisphenol A on the estradiol synthesis of ovarian granulosa cells from PCOS. Gynecological Endocrinology, 33:(1) 21-25. doi: 10.1080/09513590.2016.1184641

Milanović, M., Milošević, N., Sudji, J., Stojanoski, S., Atanacković Krstonošić, M., Bjelica, A., Milić, N., Medić Stojanoska, M. (2020): Can environmental pollutant bisphenol A increase metabolic risk in polycystic ovary syndrome? Clinica Chimica Acta, 507: 257-263. doi: https://doi.org/10.1016/j.cca.2020.05.009

Hu, Y., Wen, S., Yuan, D., Peng, L., Zeng, R., Yang, Z., Liu, Q., Xu, L., Kang, D. (2018): The association between the environmental endocrine disruptor bisphenol A and polycystic ovary syndrome: a systematic review and meta-analysis. Gynecological Endocrinology, 34:(5) 370-377. doi: 10.1080/09513590.2017.1405931

Tarantino, G., Valentino, R., Di Somma, C., D'Esposito, V., Passaretti, F., Pizza, G., Brancato, V., Orio, F., Formisano, P., Colao, A., Savastano, S. (2013): Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clinical Endocrinology (Oxford), 78:(3) 447-453. doi: 10.1111/j.1365-2265.2012.04500.x

Dominguez, M. A., Petre, M. A., Neal, M. S., Foster, W. G. (2008): Bisphenol A concentration-dependently increases human granulosa-lutein cell matrix metalloproteinase-9 (MMP-9) enzyme output. Reproductive Toxicology, 25:(4) 420-425. doi: https://doi.org/10.1016/j.reprotox.2008.05.059

Görüroğlu Öztürk, Ö. (2013): Matriks Metalloproteinaz Enzim Ailesi. Arşiv Kaynak Tarama Dergisi, 22:(2) 209-220.

Yang, Z., Shi, J., Guo, Z., Chen, M., Wang, C., He, C., Zuo, Z. (2019): A pilot study on polycystic ovarian syndrome caused by neonatal exposure to tributyltin and bisphenol A in rats. Chemosphere, 231: 151-160. doi: 10.1016/j.chemosphere.2019.05.129

Patisaul, H. B., Mabrey, N., Adewale, H. B., Sullivan, A. W. (2014): Soy but not bisphenol A (BPA) induces hallmarks of polycystic ovary syndrome (PCOS) and related metabolic co-morbidities in rats. Reproductive Toxicology, 49: 209-218. doi: 10.1016/j.reprotox.2014.09.003

Downloads

Published

2022-06-17

How to Cite

Güven, N. M., & Can Eke, B. (2022). ÇEVRESEL BİR ENDOKRİN BOZUCU KİMYASAL: BİSFENOL A VE POLİKİSTİK OVER SENDROMU OLUŞUMUNDA OLASI ETKİLERİ. Türk Bilimsel Derlemeler Dergisi, 15(1), 1–41. Retrieved from https://derleme.gen.tr/index.php/derleme/article/view/402

Issue

Section

Articles

Most read articles by the same author(s)